AFSP expert touts promise of ketamine‐buprenorphine approach
Mental Health Weekly · 25.05.2026 · 36 (21) · 6-7
DOI: 10.1002/mhw.34881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mental Health Weekly, online erschienen am 21.05.2026. Verfasst von Valerie A. Canady.
Abstract (Originalsprache)
New findings published this month in The American Journal of Psychiatry (AJP) on the use of ketamine followed by ultra‐low‐dose buprenorphine to sustain reductions in suicidal ideation are drawing attention from suicide prevention experts, who say the approach may help address a long‐standing gap in treatment during high‐risk periods following a crisis (see related story, p. 3).
Zitieren
APA
Canady, V. A. (2026). AFSP expert touts promise of ketamine‐buprenorphine approach. Mental Health Weekly, 36(21), 6-7. https://doi.org/10.1002/mhw.34881
Vancouver
Canady VA. AFSP expert touts promise of ketamine‐buprenorphine approach. Mental Health Weekly. 2026;36(21):6-7. doi:10.1002/mhw.34881
BibTeX
@article{Canady2026,
author = {Canady, Valerie A.},
title = {AFSP expert touts promise of ketamine‐buprenorphine approach},
journal = {Mental Health Weekly},
year = {2026},
volume = {36},
number = {21},
pages = {6--7},
doi = {10.1002/mhw.34881}
}
EUVIMED